Scarica l'app Stockscreener
1.56
3.11%
-0.05
Dopo l'orario di chiusura:
1.56
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PACB Giù?
Forum
Previsione
Precedente Chiudi:
$1.61
Aprire:
$1.625
Volume 24 ore:
6.68M
Relative Volume:
1.09
Capitalizzazione di mercato:
$484.54M
Reddito:
$160.03M
Utile/perdita netta:
$-128.58M
Rapporto P/E:
-3.6551
EPS:
-0.4268
Flusso di cassa netto:
$-121.21M
1 W Prestazione:
-7.14%
1M Prestazione:
+13.87%
6M Prestazione:
-19.59%
1 anno Prestazione:
+4.00%
Intervallo 1D:
$1.52
$1.64
Intervallo di 1 settimana:
$1.48
$1.72
Portata 52W:
$1.09
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Nome
Pacific Biosciences Of California Inc
Settore
Industria
Telefono
650-521-8000
Indirizzo
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.56 | 484.54M | 160.03M | -128.58M | -121.21M | -0.4268 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-06 | Downgrade | Barclays | Equal Weight → Underweight |
| 2024-11-11 | Downgrade | UBS | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-17 | Aggiornamento | UBS | Neutral → Buy |
| 2023-10-31 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-06-30 | Iniziato | Goldman | Buy |
| 2023-05-10 | Iniziato | Barclays | Equal Weight |
| 2023-03-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2023-01-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-01-21 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Neutral |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-09-27 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Iniziato | Cowen | Outperform |
| 2017-11-03 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Downgrade | CL King | Buy → Neutral |
| 2016-11-03 | Reiterato | Cantor Fitzgerald | Buy |
| 2016-06-27 | Iniziato | CL King | Buy |
| 2016-04-15 | Iniziato | First Analysis Sec | Overweight |
| 2016-02-04 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Reiterato | Cantor Fitzgerald | Buy |
| 2015-10-23 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-02-04 | Reiterato | Maxim Group | Buy |
| 2013-09-26 | Reiterato | Maxim Group | Buy |
| 2013-01-14 | Reiterato | Maxim Group | Buy |
Mostra tutto
Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie
Pacific director Christopher M. Smith resigns from board - TradingView
[8-K] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Reports Material Event - Stock Titan
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now - TradingView
WST Completes SmartDose Sale to AbbVie to Focus on Core Growth - TradingView
Here's Why You Should Add PacBio Stock to Your Portfolio Now - Yahoo Finance
Pacific Biosciences updates its sequencing strategy. Investors watch long-read technology - ad-hoc-news.de
Pacific Biosciences of California (PACB) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Is Pacific Biosciences (PACB) The Best Rising Penny Stock? - Insider Monkey
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 2500 Growth Benchmark - marketscreener.com
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 2000 Growth Benchmark - marketscreener.com
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 3000E Growth Benchmark - marketscreener.com
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 3000 Growth Benchmark - marketscreener.com
PacBio (PACB) Stock Faces Mixed Analyst Target Changes After Valuation Revisions - Yahoo Finance
Enterprise value to EBIT forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB - TradingView
Pacific Biosciences of California, Inc. Actuals & Estimates (NASDAQ:PACB) - TradingView
PACIFIC BIOSCIENCES OF CALIFORNIA ROE % Adjusted to Book Val - GuruFocus
Enterprise value to revenue forward of Pacific Biosciences of California, Inc. – FWB:P09 - TradingView
Enterprise value to EBIT forward of Pacific Biosciences of California, Inc. – FWB:P09 - TradingView
PACB Forecast — Price Target — Prediction for 2027 - TradingView
PACB Stock Gains Focus As New Sequencing Tech Slashes Genome Costs - StocksToTrade
Price to book forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB - TradingView
Pacific Biosciences of California launches kit to streamline high-throughput sequencing operations - Traders Union
Pacific Biosciences of California Inc (PACB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Price to sales forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB - TradingView
Enterprise value to EBITDA forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB - TradingView
PACB & Blank Bio partner to advance RNA foundation models in oncology - MSN
Pacific Biosciences of California Inc (PACB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pacific Biosciences of California Inc (PACB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pacific Biosciences of California Inc (PACB) Institutional Confidence - TradingKey
Pacific Biosciences of California Inc - TradingKey
Pacific Biosciences of California Inc (PACB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pacific Biosciences of California Inc (PACB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pacific Biosciences of California Inc (PACB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Is Pacific Biosciences of California, Inc. (PACB) One of the Best Genomics Stocks to Buy According to Wall Street? - Insider Monkey
5 Best Genomics Stocks to Buy According to Analysts - Insider Monkey
PacBio Announces a Private Convertible Exchange Transaction of $ - GuruFocus
Here's why you should add PacBio stock to your portfolio now - MSN
Pacific Biosciences of California Company Profile & Introduction - Moomoo
How The Pacific Biosciences (PACB) Investment Narrative Is Evolving Without New Analyst Targets - Yahoo Finance
Pacific Biosciences of California, Inc. 8-K Filing: 2020 Equity Incentive Plan Amendment, Stockholder Voting Results & Company Information (June 2026) – Minichart - Minichart
Pacific Biosciences (PACB) director receives 223,492 stock options at $1.58 strike - Stock Titan
Christopher Gibson (NASDAQ: PACB) receives 74,497 stock options grant - Stock Titan
PACIFIC BIOSCIENCES (PACB) director granted 223,492 stock options at $1.58 - Stock Titan
Director at Pacific Biosciences (PACB) receives 223,492 stock options grant - Stock Titan
PACB (PACB) director granted 223,492 stock options at $1.58 exercise price - Stock Titan
Pacific Biosciences reserves 16,000,000 additional shares under 2020 Equity Incentive Plan - TradingView
Director William W. Ericson granted 223,492 PACB options at $1.58 exercise price - Stock Titan
Director John Milligan receives 223,492 options at PacBio (PACB) - Stock Titan
PacBio (PACB) director Kathy Ordonez receives 223,492 stock options at $1.58 - Stock Titan
Pacific Biosciences Of California Inc Azioni (PACB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):